Fig. 3: GREB1 and MITF expression is correlated with melanoma cases.

A Serial sections of nevi were stained with hematoxylin-eosin (HE) (a), anti-GREB1(#2) (b, c) or anti-MITF (d) antibody. The boxed region in (b) was enlarged in (c). To distinguish from melanin pigment, the staining was visualized using the Warp Red Chromogen Kit, and sections counterstained with hematoxylin. Scale bars, 500 μm (a, b); 100 μm (c, d). B Primary melanoma tissues were stained with HE (a), anti-GREB1(#2) (b, c), or anti-MITF (d) antibody. The boxed region in (b) was enlarged in c. The staining was visualized as in A. Scale bars, 500 μm (a, b); 100 μm (c, d). C, D The distributions of the IHC scores (0–3) for GREB1 or MITF in the nevi and primary melanoma sections are shown as percentages (C). The melanoma samples were classified into two groups, depending on tumor thickness – smaller (N = 26) or larger (N = 63) than 1.5 mm. The distributions of the IHC scores for GREB1 or MITF are shown as percentages (D). E Scatter plots depict the relationship between the GREB1 and MITF scores in melanoma (N = 89). The size of the dots indicates the number of identical scores. The solid line indicates a linear fit. R and P represent the Pearson’s correlation coefficient and P-value, respectively. F Serial sections of a single melanoma specimen were stained with anti-GREB1(#2) (a) or anti-MITF antibody (b), and the respective staining intensities for individual cells were quantified with HALO soft and pseudo-colored into four levels: absent, weak, intermediate, and strong (c, d). Scale bars, 500 μm (a–d).